Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Sid Sahoo
Period: Reporting period mapped to calendar 2025 Q2.
- Questions
- 1on tracked calls
- Challenge rate
- 0%none of 1 questionLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 1 of 1 question from 1 company
ZTSZoetis1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q2
you have said that you had clubbed it under other franchise, expected to grow double digit this year. So what is the current expectation in the second half?
Show response
Wetteny reiterated double-digit growth expectation across combined key franchises (Derm + Simparica + OA Pain) but declined product-specific guidance. On cost: emphasized addressable market is medicalized dogs still larger than treated, not maturing. Cost discipline is ongoing but separate from market maturity.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| ZTS Zoetis | 1 | —Rate withheld: fewer than 3 questions |
- ZTSZoetis · 1 question—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Revenue Growth1
- Margin1